GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (WBO:LLYC) » Definitions » Cyclically Adjusted PS Ratio

Eli Lilly and Co (WBO:LLYC) Cyclically Adjusted PS Ratio : 25.42 (As of May. 18, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PS Ratio?

As of today (2024-05-18), Eli Lilly and Co's current share price is €708.90. Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €27.89. Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is 25.42.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

WBO:LLYC' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.48   Med: 4.92   Max: 27.1
Current: 25.86

During the past years, Eli Lilly and Co's highest Cyclically Adjusted PS Ratio was 27.10. The lowest was 2.48. And the median was 4.92.

WBO:LLYC's Cyclically Adjusted PS Ratio is ranked worse than
98.39% of 745 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs WBO:LLYC: 25.86

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eli Lilly and Co's adjusted revenue per share data for the three months ended in Mar. 2024 was €8.925. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €27.89 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PS Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.92 7.43 11.14 13.57 20.20

Eli Lilly and Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.48 16.73 18.76 20.20 26.12

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=708.90/27.89
=25.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=8.925/131.7762*131.7762
=8.925

Current CPI (Mar. 2024) = 131.7762.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 3.375 100.560 4.423
201409 3.521 100.428 4.620
201412 3.881 99.070 5.162
201503 4.022 99.621 5.320
201506 4.163 100.684 5.449
201509 4.149 100.392 5.446
201512 4.634 99.792 6.119
201603 4.110 100.470 5.391
201606 4.538 101.688 5.881
201609 4.361 101.861 5.642
201612 5.132 101.863 6.639
201703 4.628 102.862 5.929
201706 4.904 103.349 6.253
201709 4.495 104.136 5.688
201712 2.642 104.011 3.347
201803 3.835 105.290 4.800
201806 4.641 106.317 5.752
201809 4.431 106.507 5.482
201812 4.852 105.998 6.032
201903 4.580 107.251 5.627
201906 5.395 108.070 6.578
201909 5.414 108.329 6.586
201912 6.010 108.420 7.305
202003 5.817 108.902 7.039
202006 5.361 108.767 6.495
202009 5.348 109.815 6.418
202012 6.689 109.897 8.021
202103 6.266 111.754 7.389
202106 6.145 114.631 7.064
202109 6.321 115.734 7.197
202112 7.648 117.630 8.568
202203 7.824 121.301 8.500
202206 6.798 125.017 7.166
202209 7.757 125.227 8.163
202212 7.617 125.222 8.016
202303 7.197 127.348 7.447
202306 8.499 128.729 8.700
202309 9.891 129.860 10.037
202312 9.490 129.419 9.663
202403 8.925 131.776 8.925

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (WBO:LLYC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eli Lilly and Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (WBO:LLYC) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (WBO:LLYC) Headlines

No Headlines